

**Table S2. Clinical characteristics of patients pp65-Ag (Group I) and CMV DNA (Group II) positive in PBL and/or BM samples**

	<b>Group I: patients positive for pp65-AG</b>	<b>Group II: patients positive for CMV DNA</b>
<b>N. patients</b>	<b>24</b>	<b>14</b>
<b>Age (years), median (range)</b>	<b>40 (range 5-55)</b>	<b>32 (range 6-59)</b>
<b>Sex</b>	<b>12M/12F</b>	<b>7M/7F</b>
<b>Underlying diseases</b>		
<b>Acute Myeloid Leukemia</b>	<b>6</b>	<b>3</b>
<b>Chronic Myeloid Leukemia</b>	<b>4</b>	<b>3</b>
<b>Acute Lymphoid Leukemia</b>	<b>6</b>	<b>3</b>
<b>Multiple Myeloma</b>	<b>6</b>	<b>1</b>
<b>Other</b>	<b>2</b>	<b>4</b>
<b>Type of HSCT</b>		
<b>Related Donor</b>	<b>15</b>	<b>8</b>
<b>Mismatched Unrelated Donor</b>	<b>4</b>	<b>5</b>
<b>Cord Blood</b>	<b>5</b>	<b>1</b>
<b>Acute GVHD</b>	<b>14</b>	<b>5</b>
<b>Chronic GVHD</b>	<b>4</b>	<b>0</b>
<b>CMV disease</b>	<b>0</b>	<b>0</b>
<b>Death</b>	<b>11</b>	<b>3</b>